Trials / Unknown
UnknownNCT04766320
Study on TIL for the Treatment of r/r Gynecologic Tumors
A Clinical Safety and Efficacy Study on TIL for the Treatment of r/r Gynecologic Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Shanghai 10th People's Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gynecologic tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tumor Infiltrating Lymphocytes (TIL) | Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes. |
Timeline
- Start date
- 2021-01-04
- Primary completion
- 2022-12-04
- Completion
- 2025-01-31
- First posted
- 2021-02-23
- Last updated
- 2024-03-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04766320. Inclusion in this directory is not an endorsement.